VERU INC.
corporate_fare Company Profile
VERU INC. (NASDAQ:VERU) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 20 items for VERU at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-08, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for VERU spans 8-K, 10-Q, 424B5, S-3.
Recent high-impact activity:
- Veru Redirects Sabizabulin to Daraxonrasib-Resistant Pancreatic Cancer After Encouraging Preclinical Results
- Veru Pivots Sabizabulin to Pancreatic Cancer After Preclinical Win Over Daraxonrasib Resistance
- Veru Q3 Loss Narrows but Going Concern Warning Persists; Cash Runway Tightens
- Veru Narrows Q3 Loss, Fully Enrolls Obesity Trial, and Secures Key Patent Allowance
- Veru's Obesity Trial Fully Enrolled at 239 Patients, Key Patent Allowed
Financial Snapshot
Short Interest & Short Volume
13.25 days to coverFINRA reported short interest of 1,499,242 shares in VERU as of the October 30, 2026 settlement, a 2.3% increase from the prior period — about 13.3 days to cover at its recent average daily volume. On November 19, 2026, 41.0% of VERU volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Moderate riskFiling-implied dilution signals for VERU, detected from its recent SEC filings · based on capital-structure filings through 2026-07-02.
At-The-Market Offering Launched · Significant Potential Dilution
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →